BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-6. [PMID: 2564110 DOI: 10.1016/s0140-6736(89)91608-5] [Cited by in Crossref: 148] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther 2018;47:1213-9. [PMID: 29468705 DOI: 10.1111/apt.14579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis. 2013;17:161-189. [PMID: 23540496 DOI: 10.1016/j.cld.2012.12.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
3 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006;34:756-64. [PMID: 16455805 DOI: 10.1124/dmd.105.007575] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
5 Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol 2017;10:791-803. [PMID: 29051789 DOI: 10.1177/1756283X17728669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15(17): 2049-2066 [PMID: 19418576 DOI: 10.3748/wjg.15.2049] [Cited by in CrossRef: 301] [Cited by in F6Publishing: 253] [Article Influence: 23.2] [Reference Citation Analysis]
7 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
8 Siemens W, Xander C, Meerpohl JJ, Antes G, Becker G. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int 2014;111:863-70. [PMID: 25585583 DOI: 10.3238/arztebl.2014.0863] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000;76:199-206. [PMID: 10727561 DOI: 10.1136/pmj.76.894.199] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
10 Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 2002;99:13801-6. [PMID: 12370413 DOI: 10.1073/pnas.212494599] [Cited by in Crossref: 214] [Cited by in F6Publishing: 194] [Article Influence: 10.7] [Reference Citation Analysis]
11 Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155-168. [PMID: 22885388 DOI: 10.1016/j.jhep.2012.08.002] [Cited by in Crossref: 228] [Cited by in F6Publishing: 210] [Article Influence: 22.8] [Reference Citation Analysis]
12 Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001;5:98-115. [PMID: 12067457 DOI: 10.1111/j.1582-4934.2001.tb00144.x] [Reference Citation Analysis]
13 Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA. 2001;98:3369-3374. [PMID: 11248085 DOI: 10.1073/pnas.051551698] [Cited by in Crossref: 940] [Cited by in F6Publishing: 845] [Article Influence: 44.8] [Reference Citation Analysis]
14 Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;11:CD008320. [PMID: 27849111 DOI: 10.1002/14651858.CD008320.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Staudinger JL, Ding X, Lichti K. Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin Drug Metab Toxicol 2006;2:847-57. [PMID: 17125405 DOI: 10.1517/17425255.2.6.847] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
16 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
17 Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents. World J Gastroenterol 2008; 14(46): 7068-7074 [PMID: 19084913 DOI: 10.3748/wjg.14.7068] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
18 Bergasa NV, Jones EA. THE PRURITUS OF CHOLESTASIS. Clinics in Liver Disease 1998;2:391-405. [DOI: 10.1016/s1089-3261(05)70014-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Copple BL, Li T. Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res. 2016;104:9-21. [PMID: 26706784 DOI: 10.1016/j.phrs.2015.12.007] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 15.7] [Reference Citation Analysis]
20 Tack M. Problems with the MetaBLIND study: An examination of data on blinding patients in trials with patient-reported outcomes. J Health Psychol 2021;:13591053211059391. [PMID: 34875934 DOI: 10.1177/13591053211059391] [Reference Citation Analysis]
21 Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin Rev Allergy Immunol 2009;36:52-61. [PMID: 18751930 DOI: 10.1007/s12016-008-8085-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
22 Esmaeili A, Nassiri Toosi M, Taher M, Merat S, Bayani J, Fruzan Karimian Z, Esmaeili A, Moazzami B, Namazi S. A Pilot Randomized, Clinical Trial of the Anti-pruritus Effect of Melatonin in Patients with Chronic Liver Disease. Iran J Pharm Res 2021;20:462-72. [PMID: 34567175 DOI: 10.22037/ijpr.2020.112942.14024] [Reference Citation Analysis]
23 Wallace K, Cowie DE, Konstantinou DK, Hill SJ, Tjelle TE, Axon A, Koruth M, White SA, Carlsen H, Mann DA, Wright MC. The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol 2010;120:137-48. [PMID: 20416375 DOI: 10.1016/j.jsbmb.2010.04.012] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
24 Greaves MW. Pathogenesis and treatment of pruritus. Curr Allergy Asthma Rep 2010;10:236-42. [PMID: 20428977 DOI: 10.1007/s11882-010-0117-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
25 Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014;37:57-76. [PMID: 24333169 DOI: 10.1016/j.mam.2013.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
26 Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 2006;7:349-65. [PMID: 16724925 DOI: 10.2174/138920006776873526] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 5.9] [Reference Citation Analysis]
27 Lisboa LF, Asthana S, Kremer A, Swain M, Bagshaw SM, Gibney N, Karvellas CJ. Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series. Can J Gastroenterol 2012;26:799-805. [PMID: 23166903 DOI: 10.1155/2012/623862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
28 Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, Udaondo CB, Companc JP. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-20. [PMID: 1988266 DOI: 10.1007/BF01300759] [Cited by in Crossref: 95] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
29 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Wei S, Ma X, Zhao Y. Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery. Front Pharmacol 2020;11:1084. [PMID: 32765278 DOI: 10.3389/fphar.2020.01084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Iyer M, Reschly EJ, Krasowski MD. Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol 2006;2:381-97. [PMID: 16863441 DOI: 10.1517/17425255.2.3.381] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
32 Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009;156:7-27. [PMID: 19133988 DOI: 10.1111/j.1476-5381.2008.00030.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
33 Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials 2017;18:230. [PMID: 28535810 DOI: 10.1186/s13063-017-1966-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Kliewer SA. Cholesterol detoxification by the nuclear pregnane X receptor. Proc Natl Acad Sci U S A 2005;102:2675-6. [PMID: 15710871 DOI: 10.1073/pnas.0500159102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
35 Morris AB, Brown RB, Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 1993;37:1-7. [PMID: 8431003 DOI: 10.1128/AAC.37.1.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
37 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
38 Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007;46:365-71. [PMID: 17223219 DOI: 10.1016/j.jhep.2006.12.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
39 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
40 Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-439. [PMID: 11839728 DOI: 10.1136/gut.50.3.436] [Cited by in Crossref: 140] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]